03:08 AM EDT, 08/17/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) and Daiichi Sankyo's Enhertu showed a statistically significant and clinically meaningful improvement in the progression-free survival of certain lung cancer patients in a late-stage clinical study. The Destiny-Lung04 phase 3 trial evaluated Enhertu as a first-line treatment for patients with unresectable, locally advanced or metastatic HER2-mutant non-squamous non-small cell lung cancer, according to a Monday release. It compared Enhertu with platinum-pemetrexed doublet chemotherapy plus pembrolizumab, the global standard of care for patients with the condition. The drug's safety profile in the trial was generally in line with its known profile and no new safety concerns were flagged. The companies will continue Destiny-Lung04 as planned to assess secondary endpoints including overall survival. Results from the trial will also be shared with global regulatory agencies.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.